Description

• Navicular syndrome is a multifaceted disease and the treatment options are not always clear.
• When radiographic signs indicative of bony changes associated with navicular syndrome are present, OSPHOS is a clear choice.

What is Osphos?

• Injectable bisphosphonate solution for the control of clinical signs associated with navicular syndrome
• OSPHOS inhibits bone resorption by binding to calcium phosphate crystals (inhibiting their formation and dissolution), and by exerting direct cellular effects on osteoclasts.
• OSPHOS is supplied as 15 mL (900 mg) of clodronate disodium (60 mg/mL) per vial and is ready-to-use (no reconstitution or dilution required).